REGENXBIO Inc.

22.61+0.0500+0.22%Vol 112.06K1Y Perf -32.07%
Nov 25th, 2022 13:00 DELAYED
BID22.11 ASK23.21
Open22.56 Previous Close22.56
Pre-Market- After-Market-
 - -  - -%
Target Price
54.10 
Analyst Rating
Moderate Buy 1.72
Potential %
139.28 
Finscreener Ranking
★★★★+     55.92
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★★+     58.77
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★★     73.40
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
22.20 
Earnings Rating
Neutral
Market Cap978.85M 
Earnings Date
3rd Nov 2022
Alpha0.01 Standard Deviation0.17
Beta0.97 

Today's Price Range

22.4723.24

52W Range

18.6936.35

5 Year PE Ratio Range

-9.4022.30

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
4.15%
1 Month
-1.52%
3 Months
-27.51%
6 Months
12.04%
1 Year
-32.07%
3 Years
-45.53%
5 Years
-23.74%
10 Years
-

TickerPriceChg.Chg.%
RGNX22.610.05000.22
AAPL148.11-2.9600-1.96
GOOG97.60-1.2200-1.23
MSFT247.49-0.0900-0.04
XOM113.21-0.4000-0.35
WFC47.440.11000.23
JNJ177.240.23000.13
FB196.640.99000.51
GE88.140.27000.31
JPM136.740.26000.19
 
ProfitabilityValueIndustryS&P 500US Markets
86.50
23.40
25.80
-184.90
10.39
RevenueValueIndustryS&P 500US Markets
480.03M
11.09
96.51
120.59
Earnings HistoryEstimateReportedSurprise %
Q03 2022-1.55-1.75-12.90
Q02 2022-1.44-1.58-9.72
Q01 2022-1.29-1.62-25.58
Q04 20214.286.6755.84
Q03 2021-0.87-1.37-57.47
Q02 2021-1.08-1.36-25.93
Q01 2021-1.13-1.20-6.19
Q04 20201.11-1.24-211.71
Earnings Per EndEstimateRevision %Trend
12/2022 QR-0.822.38Positive
12/2022 FY-5.34-2.10Negative
3/2023 QR-1.68-1.20Negative
12/2023 FY-3.061.92Positive
Next Report Date-
Estimated EPS Next Report-1.55
Estimates Count4
EPS Growth Next 5 Years %11.80
Volume Overview
Volume112.06K
Shares Outstanding43.29K
Shares Float28.27M
Trades Count2.67K
Dollar Volume2.55M
Avg. Volume268.66K
Avg. Weekly Volume179.05K
Avg. Monthly Volume293.62K
Avg. Quarterly Volume333.33K

REGENXBIO Inc. (NASDAQ: RGNX) stock closed at 22.61 per share at the end of the most recent trading day (a 0.22% change compared to the prior day closing price) with a volume of 112.06K shares and market capitalization of 978.85M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 257 people. REGENXBIO Inc. CEO is Kenneth T. Mills.

The one-year performance of REGENXBIO Inc. stock is -32.07%, while year-to-date (YTD) performance is -30.86%. RGNX stock has a five-year performance of -23.74%. Its 52-week range is between 18.69 and 36.35, which gives RGNX stock a 52-week price range ratio of 22.20%

REGENXBIO Inc. currently has a PE ratio of 12.60, a price-to-book (PB) ratio of 1.67, a price-to-sale (PS) ratio of 1.95, a price to cashflow ratio of 5.60, a PEG ratio of 2.32, a ROA of 9.43%, a ROC of 15.84% and a ROE of 15.43%. The company’s profit margin is 10.39%, its EBITDA margin is 25.80%, and its revenue ttm is $480.03 Million , which makes it $11.09 revenue per share.

Of the last four earnings reports from REGENXBIO Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-1.55 for the next earnings report. REGENXBIO Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for REGENXBIO Inc. is Moderate Buy (1.72), with a target price of $54.1, which is +139.28% compared to the current price. The earnings rating for REGENXBIO Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

REGENXBIO Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

REGENXBIO Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 10.77, ATR14 : 1.19, CCI20 : 42.34, Chaikin Money Flow : -0.05, MACD : -0.30, Money Flow Index : 59.03, ROC : 8.65, RSI : 52.23, STOCH (14,3) : 71.26, STOCH RSI : 1.00, UO : 52.95, Williams %R : -28.74), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of REGENXBIO Inc. in the last 12-months were: Allan M. Fox (Sold 112 869 shares of value $3 915 359 ), Steve Pakola (Sold 1 598 shares of value $53 933 ), Vittal Vasista (Option Excercise at a value of $25 415), Vittal Vasista (Sold 27 280 shares of value $913 648 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (55.56 %)
5 (55.56 %)
6 (60.00 %)
Moderate Buy
1 (11.11 %)
1 (11.11 %)
1 (10.00 %)
Hold
3 (33.33 %)
3 (33.33 %)
3 (30.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.72
Moderate Buy
1.72
Moderate Buy
1.65

REGENXBIO Inc.

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa).

CEO: Kenneth T. Mills

Telephone: +1 240 552-8181

Address: 9600 Blackwell Road, Rockville 20850, MD, US

Number of employees: 257

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

29%71%

Bearish Bullish

53%47%

TipRanks News for RGNX

Thu, 04 Aug 2022 17:25 GMT Analysts Offer Insights on Healthcare Companies: RegenXBio (RGNX) and Autolus Therapeutics (AUTL)

- TipRanks. All rights reserved.

Thu, 04 Aug 2022 13:13 GMT RegenXBio (RGNX) Receives a Buy from Berenberg Bank

- TipRanks. All rights reserved.

News

Stocktwits